AI trial accelerator hits 100 million patient milestone

Clinical data analytics expert Phesi has said its AI-driven Trial Accelerator now contains data from 100 million patients, a critical milestone.

The company has also published the second version of its Digital Patient Profile Catalog (DPP), covering six more indications to help make digital twin creation a reality for more diseases.

Each DPP delivers a statistical view of patient attributes to improve protocol design and accelerate the adoption of digital trial arms. The new DPPs are: Relapsed/ Refractory Follicular Lymphoma, CDKL5, Chronic Migraine, Episodic Migraine, Stroke – Acute Ischemic, and Acute Coronary Syndrome.

“Collating data from 100 million patients is a huge milestone for Phesi. For almost two decades we have been gathering and structuring a wealth of data for sponsors and clinical trial planners,” commented Dr Gen Li, President, Phesi. “Context is key: Phesi is able to identify where and when specific data was generated, by whom (study investigators), and how (study design) to provide contextualised data that delivers precision, insights, and certainty to clinical development teams.

We are committed to continuing to innovate and support our clients to make breakthroughs, and deliver smarter cures to patients, faster.” The second edition of the Digital Patient Profile Catalog contains granular patient data across 34 indications both at cohort level and patient level.

The profiles will be used by sponsors to develop Digital Twins and Digital Trial Arms as part of clinical development strategies. DPPs also support wider adoption of single arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts. As well as 12 oncology profiles, the catalog will cover 22 other prevalent diseases. The addition of stroke is particularly crucial, with Phesi’s recent analysis of all clinical trials in 2023 finding that stroke is now the third most-studied disease area worldwide. “We are continually refining the methodology by which we create patient profiles,” explained Jonathan Peachey, COO and Board Director, Phesi.“In this way, we empower sponsors to make data-led decisions in the trial planning process, as well as enabling them to use digital twins and the next generation of digital control arms. We’ve seen the popularity of digital twins increase, but tools like the Digital Patient Profile are what make these twins a reality.”

The traditional data management function of collecting and interpreting patient data from clinical trials is transforming. Digitalsed patient data can be used to enhance or even replace those collected from clinical trials. Phesi’s Trial Accelerator delivers these advances directly to its users. These latest updates to the platform represent an accumulation of almost 20 years’ worth of effort collating data from product and disease registries, data from electronic health records, medical claims data, and data gathered from almost 100,000 dynamically updated sources. 


Recent Issues